The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

NCT ID: NCT07027306

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

648 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-01

Study Completion Date

2030-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an international multicenter prospective observational study. Patients with radiologically confirmed, symptomatic, single- or multilevel contiguous TL (from T1 to L5) fractures as a result of primary osteoporosis will be recruited from participating clinics/hospitals (ie, study sites). Fractures included are insufficiency fractures (confirmed by magnetic resonance imaging \[MRI\]) and traumatic fractures (low-energy trauma, confirmed by computed tomography \[CT\] or MRI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an international multicenter prospective observational study. Postmenopausal women ≥ 50 years old and men \> 60 years old with radiologically confirmed, symptomatic, single- or multilevel contiguous TL (from T1 to L5) fractures as a result of primary osteoporosis will be recruited from participating clinics/hospitals (ie, study sites). Fractures included are insufficiency fractures (confirmed by magnetic resonance imaging \[MRI\]) and traumatic fractures (low-energy trauma, confirmed by computed tomography \[CT\] or MRI).

All osteoporotic TL fractures will be classified using the OF classification system (OF 1 to OF 5). Only the most severe fracture will be used to calculate the OF score. The OF score will be subsequently calculated to aid the surgeons' decision making on the initial treatment plan, which is categorized as either nonsurgical or surgical treatment.

To address the primary study objective, depending on whether the treating surgeons' eventual initial treatment decisions agree with the OF score recommendations, patients will be divided into two groups: 1) patients whose initial treatment is in accordance with the OF score recommendations (the Accordance group), and 2) patients whose initial treatment is in discordance with the OF score recommendations (the Discordance group). Accordance refers to 1) when the OF score is \> 6, surgical treatment is prescribed by the treating surgeons, 2) when the OF score is \< 6, nonsurgical treatment only is prescribed by the treating surgeons, and 3) when the OF score is 6, either surgical or nonsurgical treatment is prescribed (Note: any surgeons' decision is deemed in accordance with the OF score as the system leaves the decision to the surgeons' discretion in this situation).

Accordance/Discordance group assignment is based on the agreement/discrepancy between the eventual treatment and the recommendations from the OF score that is obtained up to Day 0, although OF scores may be calculated at follow-ups (FUs) for subsequent treatment decision making (eg, whether the treatment plan needs to be modified).

Depending on the actual initial treatment assigned to the patients by the treating surgeons, patients will be divided into two groups: 1) patients assigned to receive nonsurgical treatment (the Nonsurgical group), and 2) patients assigned to receive surgery (the Surgical group).

Day 0 refers to the day when the initial treatment is decided and starts (categorized as nonsurgical or surgical treatment). Subsequent FUs will be calculated in reference to Day 0. Patients will be followed up clinically at discharge, 6 weeks, 3 months, 6 months, and 12 months.

The primary outcome of the study is the return to the mobility level before the injury or symptom onset (as reported by the patient). The FU period for the primary endpoint of the study is 3 months (short-term), and 12 months for the secondary endpoints (long-term).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporotic Fractures Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OF score accordance group

Initial treatment decision in accordance with the OF score recommendations

Posterior stabilization (pedicle screws)

Intervention Type PROCEDURE

* Any other type of solely vertebral augmentation (stents, etc.), specify
* Posterior stabilization (pedicle screws)
* Posterior stabilization (pedicle screws) with kyphoplasty/vertebroplasty
* Posterior stabilization (pedicle screws) with screw augmentation
* Posterior stabilization (pedicle screws) with screw augmentation and kyphoplasty/vertebroplasty
* Posterior stabilization (pedicle screws) with vertebral osteotomy (pedicle subtraction osteotomy or similar)
* Combined posterior and anterior stabilization

OF score discordance group

Initial treatment decision in discordance with the OF score recommendations

Posterior stabilization (pedicle screws)

Intervention Type PROCEDURE

* Any other type of solely vertebral augmentation (stents, etc.), specify
* Posterior stabilization (pedicle screws)
* Posterior stabilization (pedicle screws) with kyphoplasty/vertebroplasty
* Posterior stabilization (pedicle screws) with screw augmentation
* Posterior stabilization (pedicle screws) with screw augmentation and kyphoplasty/vertebroplasty
* Posterior stabilization (pedicle screws) with vertebral osteotomy (pedicle subtraction osteotomy or similar)
* Combined posterior and anterior stabilization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Posterior stabilization (pedicle screws)

* Any other type of solely vertebral augmentation (stents, etc.), specify
* Posterior stabilization (pedicle screws)
* Posterior stabilization (pedicle screws) with kyphoplasty/vertebroplasty
* Posterior stabilization (pedicle screws) with screw augmentation
* Posterior stabilization (pedicle screws) with screw augmentation and kyphoplasty/vertebroplasty
* Posterior stabilization (pedicle screws) with vertebral osteotomy (pedicle subtraction osteotomy or similar)
* Combined posterior and anterior stabilization

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Kyphoplasty Vertebroplasty

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women ≥ 50 years old or men \> 60 years old

o Menopause refers to amenorrhea for 1 complete year.
* Radiologically confirmed new diagnosis of symptomatic, single or multilevel TL (from T1 to L5) fractures, ie, the index fracture(s).

* In case of a multilevel fracture, the fracture must be contiguous.
* The index fracture is confirmed by MRI as an insufficiency (or fragility) fracture or is confirmed by CT or MRI as traumatic fracture (low-energy trauma)
* The index fracture(s) is a result of primary osteoporosis. Diagnosis of primary osteoporosis is based on any of the followings in the absence of causes for secondary osteoporosis (such as long-term use of steroids, rheumatoid arthritis, type 1 diabetes mellitus \[DM\], and other metabolic bone disorders \[eg, rickets/osteomalacia, Paget's disease, osteogenesis imperfecta, and primary hyperparathyroidism\]) \[13-15\]:

* A T-score ≤ -2.5 in the lumbar spine, femoral neck, total hip, or 1/3 radius
* Presence of fragility fracture (either a previous fragility fracture or the index fracture is a fragility fracture). Fragility fractures are fractures due to no or low-energy trauma, eg, slips, trips, or falls from less than double the body height, and heavy lifting.
* The index osteoporotic TL fracture being classified based on the OF Classification from OF 1 to OF 5:

* OF 1: No deformation (vertebral body edema on MRI using short tau inversion recovery \[STIR\] sequence)
* OF 2: Deformation of one endplate
* OF 3: Deformation of one endplate with distinct posterior wall involvement
* OF 4: Deformation of both endplates with/without posterior wall involvement
* OF 5: Injuries with anterior or posterior tension band failure
* Ability to provide informed consent according to the EC/IRB defined and approved procedures

Exclusion Criteria

* Patients with spinal tumors
* Patients with concomitant cervical fractures
* Patients showing any signs of spinal infections
* Patients with fractures due to high-energy or high-impact trauma, eg, a fall from double the body height or higher, motor vehicle accident with \> 100 km/h in cars with airbags, or motor vehicle accident \> 50 km/h without airbags, polytrauma
* Patients with concomitant fracture in the pelvis, upper extremities, and/or lower extremities which could affect the main study outcomes (specifically, patient mobility and pain)
* Patients for whom no FUs are possible
* Previous instrumented surgery in the affected spine levels
* Patients with single-level fracture or contiguous multilevel fracture adjacent to previous instrumented surgery
* Patients who are mentally impaired and therefore not able to adhere to the study procedures and data collection
* Patients who are bedridden before the index fracture
* Recent history of substance abuse (ie, recreational drugs and alcohol) that would preclude reliable assessments
* Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AO Foundation, AO Spine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Klaus Schnake, MD

Role: PRINCIPAL_INVESTIGATOR

Center for Spinal and Scoliosis Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Francisco (USCF) Department of Orthopaedic Surgery

San Francisco, California, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Sanatorio Güemes

Buenos Aires, , Argentina

Site Status

Cajuru University Hospital

Curitiba, , Brazil

Site Status

Department of Orthopedic Surgery, Clinica Alemana de Santiago

Santiago, , Chile

Site Status

Orthopaedic Department, Assiut University Hospitals, Faculty of Medicine

Asyut, , Egypt

Site Status

Tampere University Hospital

Tampere, , Finland

Site Status

Center for Spinal and Scoliosis Surgery, Malteser Waldkrankenhaus St. Marien

Erlangen, , Germany

Site Status

PGIMER - Postgraduate Institute of Medical Education and Research

Chandigarh, , India

Site Status

Dokkyo Medical University Hospital

Tochigi, , Japan

Site Status

Island Hospital Spine Centre

George Town, , Malaysia

Site Status

Spiatlul Clinic De Urgenta, "Profesor Doctor Nicolae Oblu"

Iași, , Romania

Site Status

Security Force Hospital

Riyāḑ, , Saudi Arabia

Site Status

Spital Emmental - Orthopädie Sonnenhof

Burgdorf, , Switzerland

Site Status

King's College Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Chile Egypt Finland Germany India Japan Malaysia Romania Saudi Arabia Switzerland United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Benjamin Bretzinger

Role: CONTACT

+41 79 814 01 48

Maria C Medina Giner

Role: CONTACT

0795456120

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ashraf El Naga, MD

Role: primary

Alexander R Vaccaro, MD

Role: primary

Emiliano Vialle, MD

Role: primary

Ratko Yurac, MD

Role: primary

Mohammad El-Sharkawi, MD

Role: primary

Marko Neva, MD

Role: primary

Klaus Schnake, MD

Role: primary

Vishal Kumar, MD

Role: primary

Masahito Takahata, MD

Role: primary

Kim Soon Oh, MD

Role: primary

Eugen Cezar Popescu, MD

Role: primary

Ahmed Alzahrani, MD

Role: primary

Sebastian Bigdon, MD

Role: primary

Gordan Grahovac, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TL-OF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.